During the last session, Moderna Inc (NASDAQ:MRNA)’s traded shares were 2.01 million, with the beta value of the company hitting 1.61. At the end of the trading day, the stock’s price was $36.75, reflecting an intraday loss of -0.51% or -$0.19. The 52-week high for the MRNA share is $170.47, that puts it down -363.86 from that peak though still a striking 2.59% gain since the share price plummeted to a 52-week low of $35.80. The company’s market capitalization is $14.14B, and the average intraday trading volume over the past 10 days was 13.37 million shares, and the average trade volume was 6.44 million shares over the past three months.
Moderna Inc (MRNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.52. MRNA has a Sell rating from 2 analyst(s) out of 17 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 12 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.62.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Moderna Inc (NASDAQ:MRNA) trade information
Moderna Inc (MRNA) registered a -0.51% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.51% in intraday trading to $36.75, hitting a weekly high. The stock’s 5-day price performance is -7.59%, and it has moved by -31.17% in 30 days. Based on these gigs, the overall price performance for the year is -52.36%. The short interest in Moderna Inc (NASDAQ:MRNA) is 34.38 million shares and it means that shorts have 7.59 day(s) to cover.
The consensus price target of analysts on Wall Street is $145, which implies an increase of 74.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $55 and $304 respectively. As a result, MRNA is trading at a discount of -727.21% off the target high and -49.66% off the low.
Moderna Inc (MRNA) estimates and forecasts
Statistics show that Moderna Inc has outperformed its competitors in share price, compared to the industry in which it operates. Moderna Inc (MRNA) shares have gone down -77.59% during the last six months, with a year-to-date growth rate more than the industry average at 23.44% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -601.88% this quarter and then jump 0.73% in the quarter after that. In the rating firms’ projections, revenue will decrease -51.94% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.01B as predicted by 13 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 235.09M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.81B and 167M respectively. In this case, analysts expect current quarter sales to shrink by -64.20% and then jump by 40.77% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -20.02%. While earnings are projected to return 23.56% in 2024.
MRNA Dividends
Moderna Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Moderna Inc insiders own 9.52% of total outstanding shares while institutional holders control 71.55%, with the float percentage being 79.08%. BAILLIE GIFFORD & CO is the largest shareholder of the company, while 1214.0 institutions own stock in it. As of 2024-06-30, the company held over 43.45 million shares (or 11.3741% of all shares), a total value of $5.16 billion in shares.
The next largest institutional holding, with 39.56 million shares, is of VANGUARD GROUP INC’s that is approximately 10.3568% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.7 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Moderna Inc (MRNA) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 10.91 shares. This amounts to just over 2.83 percent of the company’s overall shares, with a $400.18 million market value. The same data shows that the other fund manager holds slightly less at 8.56, or about 2.22% of the stock, which is worth about $313.98 million.
